Clinical trial · Interventional
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
A Randomized, Double Blind, Placebo-Controlled Trial of Celecoxib in Patients With Advanced Cancer
NCT00093678CI-TRIAL-00019394withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients. PURPOSE: This randomized clinical trial is studying celecoxib to see how well it works in managing pain, weight loss, and weakness in patients with advanced cancer.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Pain | — | UNRESOLVED | — |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anticachectic therapy | Procedure | — | UNRESOLVED |
| celecoxib | Drug | Celecoxib | ALIAS |
| nutritional support | Procedure | — | UNRESOLVED |
| pain therapy | Procedure | — | UNRESOLVED |
| supportive care/therapy | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed malignant tumor of 1 of the following types:
* Carcinoma
* Sarcoma
* Melanoma
* Lymphoma
* Metastatic or unresectable disease
* Clear evidence of residual disease after most recent prior treatment
* Measurable disease not required
* Patient has elected to receive supportive care only rather than active cancer treatment (e.g., palliative chemotherapy)
* Brain metastases allowed provided the following criteria are met:
* Completed treatment for CNS disease (e.g., whole brain radiotherapy, surgery, or stereotactic surgery)
* Clinically stable disease for at least 4 weeks after treatment completion
* No requirement for corticosteroids
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* ECOG 0-3
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Bilirubin ≤ 2 times upper limit of normal (ULN)
* ALT and AST ≤ 5 times ULN
Renal
* Creatinine ≤ 1.6 mg/dL
Cardiovascular
* No myocardial infarction within the past 6 months
* No transient ischemic attack within the past 6 months
* No stroke within the past 6 months
* No angina pectoris requiring medical therapy
* No other active coronary artery disease or cerebrovascular disease
Other
* No active gastrointestinal (GI) ulcer disease
* No GI bleeding
* No history of allergic reaction, urticaria, or bronchospasm after taking NSAIDs, aspirin, or sulfonamide drugs
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Concurrent hematopoietic growth factors for cytopenia or fatigue allowed
* No concurrent biologic anticancer agents
Chemotherapy
* See Disease Characteristics
Endocrine therapy
* See Disease Characteristics
* No concurrent corticosteroids for management of cancer-related symptoms or other illness
* No concurrent hormonal therapy
* Concurrent luteinizing hormone-releasing hormone therapy allowed for prostate cancer patients provided drug was initiated at least 6 months ago AND there is unequivocal evidence of progressive disease, defined by 1 of the following criteria:
* Rising prostate-specific antigen (PSA) on 3 successive measurements
* Rising PSA on 2 measurements taken at least 2 weeks apart
* New lesions on bone scan
Radiotherapy
* See Disease Characteristics
Surgery
* See Disease Characteristics
Other
* Concurrent bisphosphonates for management of osseous metastases or hypercalcemia allowed
* No concurrent cytotoxic drugs
* No other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirinReferences
Publications (0)
Data not yet available
No reference posted for this study.